Company Update This Presentation Includes Forward-Looking Statements

August 2018 Engineering the Medicines of Tomorrow Company Update This presentation includes forward-looking statements.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including its financial guidance for 2018, the commencement, timing and results of clinical trials and release of clinical data both in respect of its proprietary product candidates and of product candidates of its collaborators, the development of commercial capabilities, in particular with respect to MOR208, and the transition of MorphoSys to a fully integrated biopharmaceutical company, the expected time of launch of MOR208, interaction with regulators, including the potential approval of MorphoSys’s current or future drug candidates, including discussions with the FDA regarding the potential approval to market MOR208, and expected royalty and milestone payments in connection with MorphoSys’s collaborations. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys’s results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys’s expectations regarding its 2018 results of operations may be incorrect, MorphoSys’s expectations regarding its development programs may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that MorphoSys may fail to obtain regulatory approval for MOR208 and that data from MorphoSys’s ongoing clinical research programs may not support registration or further development of its product candidates due to safety, efficacy or other reasons), MorphoSys’s reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys’s Registration Statement on Form F-1 and other filings with the US Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

The compounds discussed in this slide presentation are investigational products being developed by MorphoSys and its partners and are not currently approved by the U.S. Food and Drug Administration (FDA), European Medicine Agency (EMA) or any other regulatory authority (except for guselkumab/Tremfya®).

MOR208 Our lead product candidate, which has been granted BTD* in r/r DLBCL by the FDA and has further potential in additional hematological malignancies; worldwide rights retained Other Proprietary Programs Multiple additional differentiated proprietary product candidates in development For MOR106, we have recently signed an exclusive agreement with Novartis Broad Clinical Pipeline 29** product candidates across proprietary and partnered development programs

Tremfya® First approved product; growing royalty participation; recent start of clinical development in Crohn’s disease Proprietary Technology Platforms Based on leading antibody platforms: over 100 active programs***

MorphoSys US Inc. Hired Jennifer Herron to head newly founded MorphoSys US Inc. and build own commercial capabilities

* Breakthrough therapy designation. ** Includes Tremfya® which we still consider a phase 3 compound due to ongoing phase 3 studies in various indications. *** Probability of success cannot be predicted. © MorphoSys AG, August 2018 3 Our Clinical Pipeline 29 Product Candidates in Clinical Development, One Product Launched

Program Partner Target Disease area Phase 1 Phase 2 Phase 3 Launched Tremfya® (Guselkumab)* Janssen IL-23p19 Psoriasis Gantenerumab Roche Amyloid-ß Alzheimer’s disease 2 MOR208 - CD19 Hematological malignancies Anetumab Ravtansine (BAY94-9343) Bayer Mesothelin (ADC) Solid tumors BAY1093884 Bayer TFPI Hemophilia BHQ880 Novartis DKK-1 Multiple myeloma Bimagrumab (BYM338) Novartis ActRIIB Musculoskeletal diseases CNTO6785 Janssen - Inflammation Ianalumab (VAY736) Novartis BAFF-R Inflammation MOR103/GSK3196165** GSK GM-CSF Inflammation 14 MOR106*** Novartis/Galapagos IL-17C Inflammation MOR202 I-Mab Biopharma**** CD38 Multiple myeloma NOV-12 (MAA868) Novartis Factor XI Prevention of thrombosis Setrusumab (BPS804) Mereo/Novartis Sclerostin Brittle bone syndrome Tesidolumab (LFG316) Novartis C5 Eye diseases Utomilumab (PF-05082566) Pfizer 4-1BB Cancer Xentuzumab (BI-836845) BI IGF-1 Solid tumors BAY2287411 Bayer Mesothelin Cancer Elgemtumab (LJM716) Novartis HER3 Cancer MOR107 (LP2-3)***** - AT2-R Not disclosed NOV–7 (CLG561) Novartis - Eye diseases NOV–8 Novartis - Inflammation NOV-9 (LKA651) Novartis - Diabetic eye diseases 12 NOV-10 (PCA062) Novartis - Cancer NOV-11 Novartis - Blood disorders NOV-13 (HKT288) Novartis - Cancer NOV-14 Novartis - Asthma PRV-300 (CNTO3157) ProventionBio TLR-3 Inflammation Vantictumab (OMP-18R5) OncoMed Fzd 7 Solid tumors ® * We still consider Tremfya a phase 3 compound due to ongoing studies in various indications. Partnered Discovery Programs ** MOR103/GSK3196165 is fully out-licensed to GSK. Proprietary Development Programs *** License agreement as of July 19, 2018. Out-licensed Proprietary Developments Programs **** For development in China, Hong Kong, Taiwan, Macao. ***** A phase 1 study in healthy volunteers was completed. MOR107 is currently in preclinical investigation with a focus on oncology indications. © MorphoSys AG, August 2018 4 Proprietary Development Programs

Program Partner Target Disease area Phase 1 Phase 2 Phase 3 . DLBCL (B-MIND) MOR208 - CD19 . DLBCL (L-MIND) . CLL (COSMOS) I-Mab MOR202 CD38 Multiple myeloma Biopharma* Novartis/ MOR106** IL-17C Atopic dermatitis Galapagos

MOR103/GSK3196165*** GSK GM-CSF Inflammation

Oncology under MOR107**** - AT2-R investigation 6 proprietary or co-developed programs in discovery and 1 in preclinical phase

* For development in China, Hong Kong, Taiwan, Macao. Proprietary Development Programs ** License agreement as of July 19, 2018. Out-licensed Proprietary Developments Programs *** MOR103/GSK3196165 is fully out-licensed to GSK. **** A phase 1 study in healthy volunteers was completed. MOR107 is currently in preclinical investigation with a focus on oncology indications.

The Product Candidate  IgG1 antibody targeting CD19  Fc-engineered to enhance target cell-killing Suggested Modes of Action  ADCC, phagocytosis and direct cytotoxicity Promising Preclinical and Clinical Package  Depletes B cells in in vitro and in vivo models  Preclinical data supports multiple combination therapies  Exploring potential biomarker for patient- specific treatment

ADCC: Antibody-Dependent Cell-Mediated Cytotoxicity ADCP: Antibody-Dependent Cell-Mediated Phagocytosis

W. Jurczak et al.; ASH 2016

Very Aggressive and Resistant Tumor  Up to 40% of all patients with DLBCL either fail to respond to or show relapse on initial Most frequently-occurring malignant therapy*** lymphoma worldwide Relapsed or Refractory DLBCL (r/r DLBCL)

 Disease is difficult to treat 33% of NHL  Prognosis is poor, especially for elderly and frail cases are patients DLBCL** 40%  Current treatment options are limited r/r  High unmet medical need DLBCL*** Non-Hodgkin Lymphoma approx. 386,000 cases*

* GLOBOCAN report 2012; ** Raut et al., 2014; *** Maurer et al., 2014; DLBCL, diffuse large B cell lymphoma; NHL, non-Hodgkin’s lymphoma

n=68 100% NE: 9 % (n=6) 90% PD: 22% 80% (n=15) 70% SD: 21% 60% (n=14) 50%

(%) PR: 18% 40% (n=12)

Overall Response Overall 30% 49% 20% CR: 31% 10% (n=21)

0% at risk: 68 37 23 17 6 3

 Median PFS: NR (95% CI 4.3 months – NR)  PFS rate at 12 months: 50.4% (95% CI 40-67%)  Median follow-up: 8.3 months

* Data cut-off December 12, 2017 DLBCL, diffuse large B cell lymphoma; ORR, objective response rate; PFS, progression-free survival; NE, non-evaluable; PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response; NR, not reached; CI, confidence interval

Parameter L-MIND Witzig et al., Czuzcman et al., Wang et al., Morschhauser et Cut-off 2011 2017 2013 al., Dec 12, 2017 ASH 2016

Compound(s) MOR208 + LEN LEN Monotherapy LEN Monotherapy RTX + LEN OBI + LEN

Phase 2 2 2/3 2 2

Evaluable patient n=68 n=108 n=51 n=32 n=71 population Objective 49% 28% 28% 28% 45% response rate Complete 31% 7% 10% 22% 16% response rate Median PFS, Not reached 2.7 3.1 2.8 4.1 months 50.4% PFS at 12 months

. MOR208 is an investigational drug that is not approved by FDA for any use. . No head-to-head clinical studies have been performed between MOR208 and the other products in this table. As such, these cross-trial comparisons of literature data have significant limitations. . The data in this table have been prepared at the request of, and for the sole benefit of, the investor community. r/r, relapsed/refractory; DLBCL, diffuse large B cell lymphoma; LEN, lenalidomide; RTX, rituximab; OBI, obinutuzumab; PFS, progression-free survival

Parameter L-MIND Dang et al., Sehn et al., Scholar-1 Juliet Zuma-1 Cut-off 2014 2017 Crump et al., Schuster et al., Neelapu et al., Dec 12, 2017 2017 2017 2017 Compound(s) MOR208 + RTX + Polatuzumab + Salvage Tisagenlecleucel Axi-CEL lenalidomide bendamustine RTX + chemotherapies (CD19 CAR-T) (CD19 CAR-T) bendamustine + radiation Phase 2 3 3 Retrospective 2 2 study Evaluable patient r/r DLBCL r/r DLBCL r/r DLBCL r/r DLBCL r/r DLBCL r/r DLBCL,FL, population n=68 n=137 n=40 n=636 n=81 PMBCL n=101 (DLBCL n=77) Objective 49% 49% 70% 26% 53%/37% 82%/48% response rate Best/@6 mo. Best/@6 mo. Complete 31% 18% 58% 7% 40%/30% 55%/46% response rate Best/@6 mo. Best/@6 mo. Median PFS, Not reached 4.2 6.7 n/a 3.2 5.8* months 50.4% PFS at 12 months . MOR208 is an investigational drug that is not approved by FDA for any use. . No head-to-head clinical studies have been performed between MOR208 and the other products in this table. As such, these cross-trial comparisons of literature data have significant limitations. . The data in this table have been prepared at the request of, and for the sole benefit of, the investor community. * For all patients; r/r, relapsed/refractory; DLBCL, diffuse large B cell lymphoma; RTX, rituximab; PFS, progression-free survival; mo., month

Indication Trial / Phase Design Timeline r/r DLBCL L-MIND Lenalidomide + MOR208 in relapsed or Fully enrolled trial; Phase 2 refractory DLBCL patients ineligible for HDCT data maturing, and ASCT analysis ongoing B-MIND Bendamustine + MOR208 vs. bendamustine + Primary analysis Phase 2/3 rituximab in relapsed or refractory DLBCL expected in Q4 2019 patients ineligible for HDCT and ASCT r/r CLL COSMOS Cohort A: MOR208 + idelalisib Updates at medical Phase 2 Cohort B: MOR208 + venetoclax conferences 2018 (EHA, June 15, 2018: Patients with r/r disease while on a BTK cohort A; late 2018: inhibitor or who are intolerant to such cohort B) treatment DLBCL Front line Under evaluation

Indolent Under evaluation lymphomas

More information about ongoing trials at clinicaltrials.gov; r/r, relapsed/refractory; DLBCL, diffuse large B cell lymphoma; HDCT, high-dose chemotherapy; ASCT, autologous stem cell transplantation; CLL, chronic lymphocytic leukemia; BTK, Bruton’s tyrosine kinase

The Product Candidate  ADCC & ADCP cell-killing mechanisms  Very low rate of infusion-related reactions  Short infusion time; enduring & deepening clinical responses as seen in phase 1/2a trial ADCC  MOR is evaluating future development in indications other than MM

Partnering Deal with I-Mab in MM (Nov. 2017)  I-Mab received exclusive development and commercialization rights in China, Taiwan, Hong Kong and Macau  Payments to MorphoSys . $20m upfront ADCP . Up to $100m milestones . Tiered, double digit royalties

 I-Mab will commence a pivotal study of MOR202 ADCC: Antibody-Dependent Cell-Mediated Cytotoxicity in MM in Q1 2019 ADCP: Antibody-Dependent Cell-Mediated Phagocytosis MM, multiple myeloma

The Product Candidate  Ylanthia antibody targeting IL-17C, a cytokine implicated in a number of inflammatory skin disorders  Originates from 50/50 co-development with Galapagos  Phase 2 trial “IGUANA” in 180 patients with moderate to severe atopic dermatitis (started May 2018)  Phase 1b study planned with subcutaneous formulation in 2018

Worldwide, exclusive partnering deal with Novartis signed July 19, 2018*  MorphoSys / Galapagos remain engaged and responsible for additional studies in atopic dermatitis  Novartis will sponsor clinical PoC studies in other indications  Up-front payment of EUR 95 million (USD 111 million**)  Front-loaded milestone package of up to approximately EUR 850 million (USD 1 billion**)  Tiered double-digit royalties (low teens to low twenties) on net commercial sales  MorphoSys and Galapagos to share all payments from Novartis equally  Novartis to fund all future research, development, manufacturing and commercialization costs

* Subject to U.S. anti-trust clearance ** Based on exchange rate: 1 EUR = 1.16336 USD (as of July 18, 2018 )

The Product Candidate  HuCAL antibody fully out-licensed to GSK in 2013 Suggested mode of action: . €22.5m upfront payment . A total of €423m milestones . Tiered, double-digit royalties on net sales . GSK is solely responsible for the development and commercialization of the compound  GSK announced data and plans for MOR103 in their recent Q2 call  Detailed Phase 2b data in rheumatoid arthritis (RA) expected to be presented at medical conference later this year*  GSK survey to support identification of unmet treatment need in RA: all patients identified joint pain as a key symptom that should be targeted**

* According to GSK’s Q2 report July 2018 ** According to GSK’s clinicalstudy register, trial identifier NCT03285191

Compound Indication Expected Newsflow  L-MIND: Continue analysis of maturing data from the study – Update likely at ASH 2018 MOR208 DLBCL  Updates on further development plans in front-line DLBCL and indolent lymphomas COSMOS: Updates at medical conferences 2018 CLL Cohort A: EHA June 16, 2018 Cohort B: late 2018 MOR202 Multiple myeloma  Final data phase 1/2a study – late 2018 (I-Mab Biopharma*)

MOR106** Atopic dermatitis Start of phase 2 trial – Q2 2018

MOR103/ Rheumatoid arthritis Data from phase 2b trial GSK3196165***

* For development in China, Hong Kong, Taiwan, Macao ** License agreement as of July 19, 2018 *** MOR103/GSK3196165 is fully out-licensed to GSK

Program Partner Target Disease area Phase 1 Phase 2 Phase 3 Launched Tremfya® (Guselkumab)* Janssen IL-23p19 Psoriasis Gantenerumab Roche Amyloid-ß Alzheimer’s disease Anetumab Ravtansine (BAY94-9343) Bayer Mesothelin (ADC) Solid tumors BAY1093884 Bayer TFPI Hemophilia BHQ880 Novartis DKK-1 Multiple myeloma Bimagrumab (BYM338) Novartis ActRIIB Musculoskeletal diseases CNTO6785 Janssen - Inflammation Ianalumab (VAY736) Novartis BAFF-R Inflammation 11 NOV-12 (MAA868) Novartis Factor XI Prevention of thrombosis Setrusumab (BPS804) Mereo/Novartis Sclerostin Brittle bone syndrome Tesidolumab (LFG316) Novartis C5 Eye diseases Utomilumab (PF-05082566) Pfizer 4-1BB Cancer Xentuzumab (BI-836845) BI IGF-1 Solid tumors BAY2287411 Bayer Mesothelin Cancer Elgemtumab (LJM716) Novartis HER3 Cancer NOV–7 (CLG561) Novartis - Eye diseases NOV–8 Novartis - Inflammation NOV-9 (LKA651) Novartis - Diabetic eye diseases NOV-10 (PCA062) Novartis - Cancer 11 NOV-11 Novartis - Blood disorders NOV-13 (HKT288) Novartis - Cancer NOV-14 Novartis - Asthma PRV-300 (CNTO3157) ProventionBio TLR-3 Inflammation Vantictumab (OMP-18R5) OncoMed Fzd 7 Solid tumors In addition, 55 partnered programs are in discovery, 24 in preclinic

* We still consider Tremfya® a phase 3 compound due to ongoing studies in various indications

The Drug  First-in-class anti-IL-23 human monoclonal antibody  Generated using MorphoSys’s HuCAL technology Status  Approved in U.S., EU, Canada, Brazil, Australia, Japan for moderate-to-severe plaque psoriasis and in Japan in addition for moderate-to-severe psoriatic arthritis  Tremfya® sales ramp-up Q2 vs. Q1 nearly doubled*; royalty income for 2018 expected in range EUR 12-17m at constant USD currency Differentiation  Superior clinical efficacy compared to Humira®  Convenience: 8-weekly sc dosing Ongoing Phase 3 Trials  Head-to-head vs. Cosentyx® in plaque psoriasis: ongoing  Psoriatic arthritis: 2 trials ongoing  Crohn’s disease: Clinical development started in July 2018

* According to Janssen‘s quarterly reports Humira® is a trademark of AbbVie Biotechnology Ltd. Cosentyx® is a trademark of Novartis AG © MorphoSys AG, August 2018 19 Technology Platform Differentiated Drugs for Treatment of Patients Suffering Serious Diseases

Proprietary Human Antibody Libraries

HuCAL Lanthipeptides  Original, ground-breaking platform  High target molecule selectivity and  First product launched high in vivo stability  25 clinical, various pre-clinical &  Agonistic or antagonistic activity discovery programs possible

Ylanthia Bi-specifics  Latest antibody library, one of the  Proprietary formats largest in the industry  Enhanced tumor cell killing via co-  Covers huge epitope space, designed for stimulation of tumor-specific effector difficult targets (e.g. MHC/peptide T cells complexes; GPCRs)  Built to deliver superior antibodies  First program in clinic

Phase 2 Phase 3

Bimagrumab (BYM338; ActRIIB) Bimagrumab (BYM338; ActRIIB) Gantenerumab (Amyloid-ß) Muscular atrophy after hip fracture surgery Sarcopenia Mild Alzheimer’s disease (open label extension)

Bimagrumab (BYM338; ActRIIB) VAY736 (BAFF-R) Guselkumab (IL-23p19) Sarcopenia Primary Sjögren’s syndrome Moderate to severe plaque psoriasis (ECLIPSE; Head-to-head with Cosentyx®)

VAY736 (BAFF-R) Xentuzumab (BI-836845; IGF-1) Guselkumab (IL-23p19) Rheumatoid arthritis Breast cancer Moderate to severe plaque psoriasis (POLARIS; Comparison to Fumaric Acid Esters) Xentuzumab (BI-836845; IGF-1) Guselkumab (IL-23p19) Prostate cancer (+ enzalutamide) Moderate to severe plaque psoriasis

Guselkumab (IL-23p19) Pustular or Erythrodermic Psoriasis

Guselkumab (IL-23p19) Palmoplantar Pustulosis

* According to clinicaltrials.gov as of August 21, 2018; anticipated primary completion dates 2018 (or 2017 without any newsflow so far). Actual events could differ.

In € million Reported FY2017 Q1-Q2 2018 Guidance FY2018

Group Revenues 66.8 10.9 67 to 72**

Proprietary R&D Expenses 99.1 39.2 87 to 97 (incl. Technology Development)

EBIT (67.6) (43.2) (55) to (65)

Cash Position End of Q2 2018***: €450.5m

Total ordinary shares issued (as of July 31, 2018): 31,809,035

* Subject to U.S. antitrust clearance. ** Revenues are expected to include royalty income from Tremfya® ranging from € 12-17 million on constant USD currency. *** Excluding the upfront payment due to the MOR106 deal, subject to U.S. antitrust clearance.

Continue to advance the development of our lead product candidate MOR208 towards regulatory approval

Build our commercial capabilities in connection with the potential future approval of MOR208

Explore options for the future development of MOR202 in indications other than MM

Realize the value of our technology platforms by using them to discover and develop additional proprietary programs

Program Partner Target Indication Phase 1 Phase 2 Phase 3 Launched Guselkumab Janssen/J&J IL23p19 Plaque psoriasis (CNTO1959) Plaque psoriasis (VOYAGE 1) Plaque psoriasis (VOYAGE 2) Pustular/erythrodermic psoriasis Plaque psoriasis Plaque psoriasis (POLARIS) Palmoplantar pustulosis Moderate to severe plaque psoriasis (SelfDoseTM device) Moderate to severe plaque psoriasis (ECLIPSE) Psoriatic arthritis (PsA) (Discover-1) Psoriatic arthritis (PsA) Chronic plaque psoriasis (pediatric participants) (PROTOSTAR) Crohn’s Disease (GALAXI 1) Gantenerumab Roche Amyloid-ß Early Alzheimer՚s disease (GRADUATE-1) Early Alzheimer՚s disease (GRADUATE-2) Mild Alzheimer’s disease (Marguerite RoAD) (OLE) Prodromal Alzheimer’s disease (Scarlett RoAD) (OLE) Genetically predisposed for Alzheimer’s disease (DIAN) MOR208 - CD19 Diffuse large B cell lymphoma (DLBCL) (B-MIND) Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (COSMOS) Diffuse large B cell lymphoma (DLBCL) (L-MIND) Anetumab Ravtansine Bayer Mesothelin Mesothelioma (MPM) (BAY94-9343) Cancer multi-indications BAY1093884 Bayer TFPI Hemophilia A or B Hemophilia BHQ880 Novartis DKK-1 Multiple myeloma (MM) (renal insufficiency) Smoldering multiple myeloma Bimagrumab Novartis ActRIIB Hip fracture surgery (efficacy, safety) (BYM338) Sarcopenia (dose-ranging) Sarcopenia (withdrawal extension study) Type 2 diabetes CNTO6785 Janssen/J&J Chronic obstructive pulmonary disease (COPD) Rheumatoid arthritis (RA)

Partnered Discovery Programs Proprietary Development Programs

Program Partner Target Indication Phase 1 Phase 2 Phase 3 Launched Ianalumab (VAY736) Novartis BAFF-R ADCC mediated B cell depletion and BAFF-R blockade (AMBER) Pemphigus vulgaris Idiopathic pulmonary fibrosis Rheumatoid arthritis (RA) Primary Sjögren's syndrome (efficacy & safety) Chronic lymphocytic leukemia (combo with ibrutinib) MOR103/GSK3196165* GSK GM-CSF Rheumatoid arthritis (RA) MOR106** Novartis/Galapagos IL-17C Atopic dermatitis MOR202 I-Mab*** CD38 Multiple myeloma (MM) Nov-12 (MAA868) Novartis Factor XI Prevention of thrombosis Atrial fibrillation Setrusumab (BPS804) Mereo/Novartis Sclerostin Brittle bone disease (OI) (Type I, III, IV) (ASTEROID) Tesidolumab (LFG316) Novartis C5 Paroxysmal nocturnal hemoglobinuria Utomilumab Pfizer 4-1BB Breast cancer (AVIATOR) (PF-05082566) Acute myeloid leukemia (AML) Advanced malignancies (combo with avelumab and PF- 04518600) (Javelin Medley) Solid tumors (combo with ISA101b vaccination) Advanced malignancies (combo with avelumab & PF- 04518600) Solid tumors (combo with PF04518600) Colorectal cancer (combo with cetuximab & irinotecan) Advanced ovarian cancer (T cell immunotherapy) R/R DLBCL & MCL (avelumab plus utomilumab-based combination therapy) Breast cancer (combo with trastuzumab emtansine or trastuzumab) Diffuse large B cell lymphoma (Javelin DLBCL) (combo with avelumab) Xentuzumab BI IGF-1 Breast cancer (BI-836845) Castration-resistant prostate cancer (CRPC) (combo with enzalutamide) Solid tumors (Japan) Solid tumors (combo with abemaciclib) EGFR mutant non-small cell lung cancer (NSCLC) BAY2287411 Bayer Mesothelin Cancer Elgemtumab (LJM716) Novartis HER3 HER2+ cancer (combo with BYL719 & trastuzumab) MOR107 (LP2-3)**** - AT2-R Not disclosed Partnered Discovery Programs * MOR103/GSK3196165 is fully out-licensed to GSK. Proprietary Development Programs ** License agreement as of July 19, 2018 *** For development in China, Hong Kong, Taiwan, Macao. Out-licensed Proprietary Developments Programs **** A phase 1 study in healthy volunteers was completed. MOR107 is currently in preclinical investigation with a focus on oncology indications. © MorphoSys AG, August, 2018 26 Clinical Programs Ongoing Clinical Trials (3)

Program Partner Target Indication Phase 1 Phase 2 Phase 3 Launched NOV-7 (CLG561) Novartis n.d. Eye diseases NOV-8 Novartis n.d. Inflammation NOV-9 (LKA651) Novartis n.d. Diabetic eye diseases NOV-10 (PCA062) Novartis n.d. Cancer NOV-11 Novartis n.d. Blood disorders NOV-13 (HKT288) Novartis n.d. Cancer NOV-14 Novartis n.d. Asthma PRV-300 (CNTO3157) ProventionBio TLR-3 Colitis (PULSE) Vantictumab Oncomed Fzd 7 Breast cancer (combo with paclitaxel) (OMP-18R5) Pancreatic cancer (combo with nap-paclitaxel & gemcitabine)

Partnered Discovery Programs

Listing in Germany on the Listing in the U.S. on the Frankfurt Stock Exchange Nasdaq Global Market Security paper Ordinary shares Security paper American depository (ORD) shares (ADS) Symbol MOR Symbol MOR ISIN DE0006632003 CUSIP 617760202 Security Code Number 5531000 ISIN US6177602025 Currency EUR Currency US-$ 1st trading day March 9, 1999 1st trading day April 19, 2018 Ratio 4 ADSs : 1 ORD Depository Bank BNY Mellon

Please see our website www.morphosys.com for more information about MorphoSys shares and ADSs.

Institution Contact

Berenberg Klara Fernandes

Bloomberg Intelligence Cinney Zhang

Bryan Garnier Gary Waanders

Commerzbank Daniel Wendorff

Deutsche Bank Gunnar Romer

Goldman Sachs Keyur Parekh

HSBC Julie Mead

Independent Research GmbH Bernhard Weininger

J.P. Morgan Cazenove James Gordon

JMP Konstantinos N. Aprilakis

Kempen & Co. Anastasia Karpova

Landesbank Baden-Württemberg Timo Kürschner

Oddo BHF Igor Kim

Royal Bank of Canada Zoe Karamanoli

Corporate Communications & IR Phone +49 (0)89 / 899 27-404 Fax +49 (0)89 / 899 27-5404 Email [email protected]

www.morphosys.com

MOR208, MOR202, MOR106, MOR103, anetumab ravtansine, gantenerumab and all other product candidates mentioned here are investigational drugs and have not been approved by the FDA or other ex-US regulatory agencies. HuCAL® , HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered trademarks of the MorphoSys Group. Tremfya® is a trademark of Janssen Biotech, Inc.